Evolving considerations for choice of hepatitis B vaccine

Area of Science:

• Public Health
• Vaccinology
• Infectious Diseases

Background:

• Hepatitis B virus (HBV) infection poses a significant public health challenge in the US, with no current cure.
• The US Department of Health and Human Services aims to eliminate HBV by 2030 through reduced incidence and mortality.
• Vaccination is the primary strategy for preventing new HBV infections.

Purpose of the Study:

• To review current Hepatitis B virus (HBV) vaccine considerations based on CDC recommendations.
• To discuss new clinical data regarding HBV vaccines.
• To evaluate the role of Heplisav-B in addressing unmet needs in HBV prevention.

Main Methods:

• Review of CDC recommendations for HBV vaccination.
• Analysis of recent clinical data on available HBV vaccines.
• Assessment of Heplisav-B's potential in the HBV prevention landscape.

Main Results:

• Four HBV vaccines, including Heplisav-B, are available for adults in the US.
• The Advisory Committee on Immunization Practices recommends all four vaccines equally for HBV prevention.
• Heplisav-B presents potential to fulfill existing gaps in HBV prevention.

Conclusions:

• The 2030 HBV elimination goal necessitates effective prevention strategies.
• Heplisav-B is a notable option among available HBV vaccines for adults.
• Emerging data and recommendations guide the optimal use of HBV vaccines for public health impact.